Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2008 Jul 5;9(4):199–206. doi: 10.1007/s10194-008-0051-9

Improving care through health economics analyses: cost of illness and headache

Francesco Saverio Mennini 1,✉, Lara Gitto 1, Paolo Martelletti 2
PMCID: PMC3451939  PMID: 18604472

Abstract

The impact of headache disorders is a problem of enormous proportions, both for individual and society. The medical literature tried to assess its effects on individuals, by examining prevalence, distribution, attack frequency and duration, and headache-related disability, as well as effects on society, looking at the socio-economic burden of headache disorders [Rasmussen (Cephalalgia 19:20–23, 1999)]; [Lanteri-Minet et al. (Pain 102:143–149, 2003)]. The issue of costs represents an important problem too, concerning both direct and indirect costs. Direct costs concern mainly expenses for drugs. Migraine has a considerable impact on functional capacity, resulting in disrupted work and social activities: many migraineurs do not seek medical attention because they have not been accurately diagnosed by a physician or do not use prescribed medication [Solomon and Price (Pharmacoeconomics 11:1–10, 1997)]. Indirect costs associated with reduced productivity represent a substantial proportion of the total cost of migraine as well. Migraine has a major impact on the working sector of the population, and therefore, determining the indirect costs outweighs the direct costs. This study will explain the notion of cost of illness, examining how it could be applied in such a framework. Then, an overview of the studies aimed at measuring direct and indirect costs of migraine and headache disorders will be carried out, later shifting on to the relationship between costs and quality of life for people affected by headache disorders. Finally, a brief review on advantages of new pharmaceuticals and preventive treatments for migraine for patients and society will outline improvements in the context of cost-effectiveness and cost-utility analysis.

Keywords: Migraine, Cost of illness, Disease costing, Economic evaluation

Full Text

The Full Text of this article is available as a PDF (178.2 KB).

Acknowledgments

This Tutorial partly results from the lesson of the Author (FSM) at the Master in Headache Medicine, Sapienza University of Rome, during the academic year 2007–2008 (http://w3.uniroma1.it/headache). This Academic Educational activity is done under the supervision of the WHO Global Campaign to Reduce the Burden of Headache Worldwide "Lifting The Burden"—Working Group for Specialist Education (SEWG) and Working Group for Outcome Measures (OMWG) (http://www.l-t-b.org).

Conflict of interest

None.

References

  • 1.Adelman JU, Seggern R. Cost considerations in headache treatment. Part 1: prophylactic migraine treatment. Headache. 1995;35(8):479–487. doi: 10.1111/j.1526-4610.1995.hed3508479.x. [DOI] [PubMed] [Google Scholar]
  • 2.Auray JP. Socio-economic impact of migraine and headaches in France. CNS Drugs. 2006;20(1):37–46. doi: 10.2165/00023210-200620001-00006. [DOI] [PubMed] [Google Scholar]
  • 3.Bigal ME, Rapoport AM, Bordini CA, Tepper SJ, Shftell FD, Speciali JG. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache. 2003;43(7):742–754. doi: 10.1046/j.1526-4610.2003.03132.x. [DOI] [PubMed] [Google Scholar]
  • 4.Blumenfeld A. Botulinum toxin type A treatment of disabling migraine headache: a randomised double-blind, placebo-controlled study. Headache. 2003;43:853–860. doi: 10.1046/j.1526-4610.2003.03163.x. [DOI] [PubMed] [Google Scholar]
  • 5.Clouse JC, Osterbaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994;28(5):659–664. doi: 10.1177/106002809402800518. [DOI] [PubMed] [Google Scholar]
  • 6.Dodick DW, Lipsy RJ. Advances in migraine management: implications for managed care organizations. Manag Care. 2004;13(5):45–51. [PubMed] [Google Scholar]
  • 7.Drummond M (1980) Principles of economic appraisal in health care, Oxford University Press
  • 8.Fishman P, Korff M, Lozano P, et al. Chronic care costs in managed care. Health Aff. 1997;16(3):239–247. doi: 10.1377/hlthaff.16.3.239. [DOI] [PubMed] [Google Scholar]
  • 9.Gagne JJ, Leas B, Lofland JH, Goldfarb N, Freitag F, Silberstein S. Quality of care measures for migraine: a comprehensive review. Dis Manag. 2007;10(3):138–146. doi: 10.1089/dis.2007.103639. [DOI] [PubMed] [Google Scholar]
  • 10.Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004;46:398–412. doi: 10.1097/01.jom.0000121151.40413.bd. [DOI] [PubMed] [Google Scholar]
  • 11.Goldberg LD. The cost of migraine and its treatment. Am J Manag Care. 2005;11(2 Suppl):S62–S67. [PubMed] [Google Scholar]
  • 12.Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med. 2007;49(4):368–374. doi: 10.1097/JOM.0b013e31803b9510. [DOI] [PubMed] [Google Scholar]
  • 13.Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–818. doi: 10.1001/archinte.159.8.813. [DOI] [PubMed] [Google Scholar]
  • 14.Lanteri-Minet M, et al. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102:143–149. doi: 10.1016/s0304-3959(02)00348-2. [DOI] [PubMed] [Google Scholar]
  • 15.Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s classification of functioning, disability and health (ICF) J Headache Pain. 2005;6(6):429–440. doi: 10.1007/s10194-005-0252-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin. 2001;17(Suppl 1):s4–s12. doi: 10.1185/0300799039117005. [DOI] [PubMed] [Google Scholar]
  • 17.Lipton RB, Stewart WF, Korff M. The burden of migraine. A review of cost to society. Pharmacoeconomics. 1994;6(3):215–221. doi: 10.2165/00019053-199406030-00005. [DOI] [PubMed] [Google Scholar]
  • 18.Lipton RB, Stewart WF, Von Korff M (1997) Burden of migraine: societal costs and therapeutic opportunities. Neurology 48(3 Suppl. 3):S4–S9 [DOI] [PubMed]
  • 19.Mennini FS, Fioravanti L, Piasini L, Palazzo F, Coloprisco G, Martelletti P (2004) A one-year economic evaluation of botulinum toxin type a treatment of chronic tension-type headaches: part I. J Headache Pain
  • 20.Pierangeli G, Cevoli S, Sancisi E, Grimaldi D, Zanigni S, Montagna P, Cortelli P. Which therapy for which patient? Neurol Sci. 2006;27(Suppl. 2):S153–S158. doi: 10.1007/s10072-006-0592-0. [DOI] [PubMed] [Google Scholar]
  • 21.Pini LA, Cainazzo MM, Brovia D. Risk benefit and cost-benefit ratio in headache treatment. J Headache Pain. 2005;6(4):315–318. doi: 10.1007/s10194-005-0219-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia. 1999;19(Suppl. 25):20–23. doi: 10.1177/0333102499019s2505. [DOI] [PubMed] [Google Scholar]
  • 23.Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics. 1997;11(Suppl. 1):1–10. doi: 10.2165/00019053-199700111-00003. [DOI] [PubMed] [Google Scholar]
  • 24.Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443–2454. doi: 10.1001/jama.290.18.2443. [DOI] [PubMed] [Google Scholar]
  • 25.Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. doi: 10.1111/j.1468-2982.2007.01288.x. [DOI] [PubMed] [Google Scholar]
  • 26.Vinding GR, Zeeberg P, Lyngberg A, Nielsen RT, Jensen R. The burden of headache in a patient population from a specialized headache centre. Cephalalgia. 2007;27(3):263–270. doi: 10.1111/j.1468-2982.2006.01273.x. [DOI] [PubMed] [Google Scholar]
  • 27.Volcy-Gomez M. The impact of migraine and other primary headaches on the health system and in social and economic terms. Rev Neurol. 2006;43(4):228–235. [PubMed] [Google Scholar]
  • 28.Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998;38(6):468–471. doi: 10.1046/j.1526-4610.1998.3806468.x. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES